CRNX - Crinetics Pharmaceuticals, Inc.
24.70 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 24.15 |
| Open | 24.16 |
| Bid | 24.52 x 900 |
| Ask | 24.60 x 3200 |
| Day's Range | 24.14 - 24.90 |
| 52 Week Range | 19.23 - 42.00 |
| Volume | 61,718 |
| Avg. Volume | 67,577 |
| Market Cap | 595.159M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.23 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 39.50 |
- GlobeNewswire•last month
Crinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for Acromegaly
Crinetics Pharmaceuticals, Inc. (CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the dosing of the first patients in the ACROBAT EVOLVE and EDGE trials for CRN00808 in patients with acromegaly. EVOLVE is a double-blind, placebo-controlled, randomized withdrawal study designed to evaluate the safety, efficacy, and pharmacokinetics of CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, in patients with acromegaly that are responders to octreotide LAR or lanreotide depot monotherapy. EDGE is an open label exploratory study designed to evaluate the safety, efficacy, and pharmacokinetics of CRN00808 in patients with acromegaly whose disease is inadequately controlled by octreotide LAR or lanreotide depot alone.
- GlobeNewswire•last month
Crinetics Pharmaceuticals Appoints Gina Ford, RPh, MBA, as Vice President, Corporate Strategy and Commercial Planning
SAN DIEGO, March 18, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- GlobeNewswire•last month
Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO2019
SAN DIEGO, March 14, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- GlobeNewswire•last month
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
SAN DIEGO, March 13, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- GlobeNewswire•2 months ago
Crinetics Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
SAN DIEGO, Feb. 21, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- Benzinga•3 months ago
Top 5 Small-Cap Winners And Losers, Week Of Jan. 7
In today’s round-up of the previous week’s top five shakers and fakers (i.e. winners and losers,), we see some major jumps or drops depending on how well company announcements were received. For some, ...
- American City Business Journals•3 months ago
At biotech's big event, a chance for execs to shape LGBTQ diversity on boards
As corporate diversity issues are in the spotlight, a small group will assemble at the J.P. Morgan Healthcare Conference to build a network of current and potential LGBTQ board members.
- GlobeNewswire•4 months ago
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 02, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- GlobeNewswire•5 months ago
New Research Coverage Highlights Chuy's, Viveve Medical, ClearSign Combustion, WhiteHorse Finance, Crinetics Pharmaceuticals, and Boston Omaha — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•5 months ago
Crinetics Pharmaceuticals to Participate in Piper Jaffray 30th Annual Healthcare Conference
SAN DIEGO, Nov. 20, 2018 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- GlobeNewswire•5 months ago
Crinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 13, 2018 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- ACCESSWIRE•9 months ago
Today’s Research Reports on Stocks to Watch: CTI BioPharma and Crinetics Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / July 19, 2018 / Shares of CTI Biopharma tanked nearly 44% yesterday while shares of Crinetics Pharmaceuticals exploded 44%. The former announced an update from an FDA meeting regarding the company's investigational drug pacritinib. Per FDA feedback, the company will now have to conduct a Phase 3 trial.
